Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Pathway Quickly Becoming Crowded In U.S.

This article was originally published in The Pink Sheet Daily

Executive Summary

Interactive chart of growing 351(k) pipeline shows that while Phase III is dominated by big players, pure-play biosimilar companies are beginning to emerge.

You may also be interested in...



Biosimilars Education: Oncobiologics/Premier Deal Aims To Boost Adoption, Data Collection

With two biosimilars set to move into Phase III this year, Oncobiologics hopes partnership with hospital services firm Premier will generate 'best practices around the optimal use of these cost-effective treatments.'

Pfizer Will Retain Infliximab Biosimilar In US After Hospira Acquisition

While European Union requires Pfizer to divest its infliximab candidate in Europe as condition of acquisition, FTC demands only that it sell off four generics.

As Biosimilar Meeting Requests Rise, So Do FDA's Performance Goal Challenges

Growing number of products participating in BsUFA program, coupled with budgetary challenges, have made FDA attainment of some early goals under the Biosimilar User Fee Act difficult.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel